Moderna Inc. ($MRNA) Stock Forecast: Down 5.7% Today

What is Moderna Inc.?

A biotechnology company known for its mRNA technology, Moderna (MRNA), witnessed a downward trend in its stock price today.

Why is Moderna Inc. going down?

MRNA stock is down 5.7% on Dec 24, 2025 14:40

• Moderna’s stock saw a decline to approximately $32.29 after a surge in late December. Several factors contributed to this movement:
• Investor worries regarding bird flu funding from CEPI and the progress of Moderna's mNEXSPIKE vaccine evaluated by the European Medicines Agency.
• Scrutiny on the company's financial moves, which include securing a $1.5 billion loan and outlining 2026 growth targets.
• Analysts have an overall "Hold" consensus rating with an average 12-month target price of $33.25, reflecting a cautious stance on the stock.
• The recent uptick in Moderna’s stock was primarily due to enhanced liquidity and cost containment rather than fundamental business growth, leading some investors to sell and reap profits. The decision aligns with concerns about declining fundamentals, like terminating the CMV program, which could impact the company's future prospects and pipeline.
• Today's bearish movement in Moderna’s stock seems to stem from profit-taking post a recent rally, investor focus on key developments and funding, and uncertainties about the company’s strategic path amidst evolving market trends.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

CVS Health's (NYSE:CVS) investors will be pleased with their notable 84% return over the last year

CVS Health Corporation (NYSE:CVS) shareholders have seen an 84% total shareholder return (TSR) in the last year, outperforming the market's 14% return. While the share price alone is up 76%, the substantial dividend payments explain the even higher TSR. Despite a 91% drop in EPS, revenue growth of 6.7% and insider buying activity suggest underlying business development.

https://finance.yahoo.com/news/cvs-healths-nyse-cvs-investors-130014087.html

Arcellx (NASDAQ:ACLX) Raised to "Strong-Buy" at Wells Fargo & Company

Wells Fargo & Company upgraded Arcellx (NASDAQ:ACLX) to a "Strong-Buy" rating. The company faces profitability challenges, as indicated by weak quarterly results and significant insider stock sales. Institutional ownership in Arcellx is high, at approximately 96%.

https://www.marketbeat.com/instant-alerts/arcellx-nasdaqaclx-raised-to-strong-buy-at-wells-fargo-company-2025-12-24/

Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna stock experienced a late-December surge followed by a significant pullback, settling around $32.29. The volatility is attributed to investor focus on bird flu funding from CEPI, the European Medicines Agency's progress on Moderna's mNEXSPIKE vaccine, and the company's financial strategies including a $1.5 billion loan and 2026 growth targets. Analysts currently hold a "Hold" consensus rating with an average 12-month price target of $33.25, reflecting the ongoing transition from a pandemic-driven business model to a multi-product biotech.

https://ts2.tech/en/moderna-stock-mrna-today-shares-cool-off-after-a-late-december-spike-as-investors-focus-on-bird-flu-funding-mnexspikes-eu-path-and-2026-growth-targets/

PPL stock price target raised to $37 from $36 at UBS on earnings tailwinds

UBS has increased its price target for PPL Corp (NYSE:PPL) to $37 from $36, while maintaining a Neutral rating on the stock, citing earnings tailwinds from public convenience order and transmission investments. The firm also raised its EPS growth forecast for PPL and identified catalysts like the Pennsylvania rate case settlement expected around 2026. This adjustment follows PPL's stronger-than-expected Q3 2025 earnings and other strategic developments.

https://www.investing.com/news/analyst-ratings/ppl-stock-price-target-raised-to-37-from-36-at-ubs-on-earnings-tailwinds-93CH-4422366

Moderna: Why I Am Selling The 'Relief Rally' (NASDAQ:MRNA)

Moderna's stock has seen a 23% rally, but the author maintains a 'Sell' rating due to deteriorating fundamentals, arguing the rally is driven by liquidity improvements and cost discipline rather than core business growth. The discontinuation of the CMV program removes a key pipeline asset, increasing reliance on declining COVID and underperforming RSV franchises. The author suggests Moderna’s strategy prioritizes survival through cost cuts, potentially sacrificing long-term pipeline value and growth visibility.

https://seekingalpha.com/article/4855444-moderna-why-i-am-selling-the-relief-rally

Trending Today

Groupon Inc. ($GRPN) Stock Forecast: Up 5.0% Today

Hologic Inc. ($HOLX) Stock Forecast: Down 0.6% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.3% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 6.1% Today

Prime Medicine ($PRME) Stock Forecast: Down 5.0% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.7% Today

Nike Inc. ($NKE) Stock Forecast: Up 5.0% Today

Bittensor ($TAO) Crypto Forecast: Down 5.1% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Down 5.3% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.1% Today

Moderna Inc. Price History

05.11.2025 - MRNA Stock was up 7.9%

• Moderna's stock experienced a surge today after a significant study from France verified the safety and effectiveness of its COVID-19 vaccine, reassuring investors about the company's primary product.
• This upward momentum was also backed by the company surpassing its 20-day moving average, indicating a short-term uptrend and optimistic earnings estimate adjustments.
• Institutional engagement with Moderna showed a mixed picture, with one entity reducing its position notably, while another entity acquired a considerable number of shares in the second quarter.
• Overall, the encouraging developments concerning the COVID-19 vaccine efficacy and technical signals played a role in the strong bullish movement witnessed in Moderna's stock today.

05.11.2025 - MRNA Stock was up 6.3%

• Moderna's positive market movement is linked to its surpassing of the 20-day moving average, indicating a favorable short-term trend and capturing the attention of traders.
• While a decrease in the stake held by Skandinaviska Enskilda Banken AB publ initially raised some concerns, the sizeable acquisition of shares by Norges Bank, alongside optimistic earnings forecast adjustments, likely bolstered investor trust in the stock.
• Despite a year-over-year revenue decline, Moderna's quarterly earnings surpassing expectations might have reassured investors regarding the company's growth prospects, playing a role in the current market positivity.
• In summary, Moderna's stock appears to have been driven upwards today by a blend of technical strength, encouraging earnings projections, and institutional investments.

04.10.2025 - MRNA Stock was down 5.1%

• MRNA stock faced a bearish trajectory attributed to various factors:
• Declining demand for the COVID-19 vaccine affecting the company's earnings forecast.
• Recent setbacks in clinical trials overshadowing positive pipeline updates and causing unease among investors.
• Despite prior stock price surges, the trend in earnings estimate revisions may not support further upward momentum.
• Reduced short interest suggesting potential waning market backing, contributing to the stock's downward pressure.

17.11.2025 - MRNA Stock was up 5.5%

• Moderna's bullish movement can be attributed to its participation in the prestigious J.P. Morgan Healthcare Conference, where it showcased its advancements in mRNA technology and its commitment to making a positive impact.
• The positive news of the CHMP backing EU approval for Moderna's new COVID-19 vaccine, mNexspike, for individuals aged 12 and older, also contributed to the stock's upward momentum.
• Despite Pfizer's disappointing revenue outlook affecting its stock and dragging down shares of vaccine rivals like Moderna, the overall market sentiment towards Moderna seems to have been buoyed by its continuous innovation and progress in developing new vaccines and therapies.
• Moderna's announcement of dosing the first patient in a Phase 1/2 study of an investigational T-cell engager for multiple myeloma further showcased the company's diversification and expansion into new treatment areas, adding to investor optimism.

11.10.2025 - MRNA Stock was up 5.0%

• The company recorded a third-quarter loss that was notably under projections, signaling a solid financial performance.
• Moderna's quarterly sales surpassed estimates, highlighting its robust revenue generation.
• The favorable outcomes in earnings and revenue suggest a promising financial trajectory for Moderna, potentially bolstering investor confidence and fueling the upward trend in its stock price.
• The revised sales forecast, coupled with the exceptional financial results, likely played a significant role in driving Moderna's stock price upward today.

18.11.2025 - MRNA Stock was up 5.1%

• Moderna's stock surged as a French study confirmed the effectiveness of its COVID-19 vaccine, showcasing a significant reduction in COVID-19 deaths among vaccinated individuals.
• The anticipation surrounding Moderna's presentation at the J.P. Morgan Healthcare Conference also contributed to the bullish momentum, highlighting the company's continued advancements in the healthcare sector.
• The broader biotech sector's positive performance, driven by successful clinical data, new drug launches, and increased M&A activity, further boosted Moderna's stock price.
• Despite facing some analyst skepticism and insider selling, Moderna's stock managed to outperform, showcasing investor confidence in the company's growth prospects and its position in the biotech industry.

23.11.2025 - MRNA Stock was down 8.8%

• Moderna CEO's decision to retain expiring stock options and show confidence in the company's recovery may have unsettled investors, contributing to the bearish movement.
• Increased stake by prominent institutional investors such as Thrivent Financial for Lutherans could signal faith in Moderna's future, but a director selling a large number of shares might have alarmed other investors.
• The funding from CEPI for a Phase 3 trial of Moderna's mRNA pandemic influenza vaccine candidate might have been overshadowed by short-term worries, impacting the stock price negatively.
• While the positive news regarding Biogen's sustained benefits for ALS patients did not have a direct influence on Moderna, it could have shifted attention and investments away from Moderna, leading to a decline in its stock performance.

23.11.2025 - MRNA Stock was down 5.0%

• Institutional investor, Thrivent Financial for Lutherans, notably increased its stake in Moderna by 600.7% in the second quarter, signaling strong institutional interest. However, concerns arose among investors due to a director selling a substantial number of shares, potentially contributing to the bearish movement.
• There are positive signs for Moderna's pipeline with the news of CEPI funding a pivotal Phase 3 trial for the company's mRNA pandemic influenza vaccine candidate. Despite this, profit-taking and worries about market saturation for vaccines could be influencing market activity.
• GSK PLC's positive quarterly earnings and guidance may have diverted investor attention from Moderna, impacting MRNA's stock performance negatively.
• The absence of specific adverse developments related to Moderna suggests that the market's bearish movement may stem from broader market sentiment or sector rotation rather than company-specific factors.

19.11.2025 - MRNA Stock was up 5.0%

• Moderna's bullish movement today could be attributed to the positive investor sentiment following its participation in the 44th Annual J.P. Morgan Healthcare Conference, where it showcased its developments in mRNA medicine.
• The news of receiving funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for its bird flu vaccine candidate might have also boosted investor confidence in Moderna's future prospects.
• Despite the muted revenues and growth concerns, the market seems to be focusing on the potential of Moderna's innovative approach to vaccine development, driving the bullish movement in the stock today.

20.10.2025 - MRNA Stock was down 5.2%

• Moderna stock saw a decrease in value after two notable revelations concerning its finances and business strategy.
• Market sentiment towards the company may have turned pessimistic, reflecting potential apprehensions regarding its future financial trajectory and strategic decisions.
• Investors could be adopting a watchful stance on Moderna until further details emerge on the implications of these announcements for the company's expansion opportunities.

24.11.2025 - MRNA Stock was down 5.7%

• Moderna’s stock saw a decline to approximately $32.29 after a surge in late December. Several factors contributed to this movement:
• Investor worries regarding bird flu funding from CEPI and the progress of Moderna's mNEXSPIKE vaccine evaluated by the European Medicines Agency.
• Scrutiny on the company's financial moves, which include securing a $1.5 billion loan and outlining 2026 growth targets.
• Analysts have an overall "Hold" consensus rating with an average 12-month target price of $33.25, reflecting a cautious stance on the stock.
• The recent uptick in Moderna’s stock was primarily due to enhanced liquidity and cost containment rather than fundamental business growth, leading some investors to sell and reap profits. The decision aligns with concerns about declining fundamentals, like terminating the CMV program, which could impact the company's future prospects and pipeline.
• Today's bearish movement in Moderna’s stock seems to stem from profit-taking post a recent rally, investor focus on key developments and funding, and uncertainties about the company’s strategic path amidst evolving market trends.

04.11.2025 - MRNA Stock was up 5.2%

• Moderna's stock has surpassed its 20-day moving average, indicating a short-term bullish trend that has caught traders' attention.
• Institutional activity surrounding Moderna has been a mix, with one entity reducing its stake significantly as another acquired a substantial number of shares.
• Analyst opinions on Moderna vary, with some recommending a "Hold" position, but the overall sentiment is positive due to strong earnings estimates.
• The increase in Moderna's stock price could be due to technical strength from crossing the moving average and favorable fundamental factors like earnings outlook, despite varying institutional investor actions.